NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status (Ascending) |
---|---|---|---|---|---|---|---|---|---|---|---|
70518-1585-00 | 70518-1585 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct. 24, 2018 | In Use | |
70518-1585-01 | 70518-1585 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 6, 2021 | Aug. 11, 2021 | In Use |
70518-1585-03 | 70518-1585 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 1, 2023 | In Use | |
70518-1585-02 | 70518-1585 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 3, 2021 | March 9, 2021 | In Use |
70518-1585-05 | 70518-1585 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 16, 2023 | In Use | |
70518-1585-04 | 70518-1585 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 9, 2023 | In Use | |
70121-1610-01 | 70121-1610 | Methylprednisolone acetate | Methylprednisolone acetate | 80.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intra-articular, Intralesional, Intramuscular, Intrasynovial, Soft Tissue | Nov. 10, 2023 | In Use | |
70121-1610-05 | 70121-1610 | Methylprednisolone acetate | Methylprednisolone acetate | 80.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intra-articular, Intralesional, Intramuscular, Intrasynovial, Soft Tissue | Nov. 10, 2023 | In Use | |
70121-1609-01 | 70121-1609 | Methylprednisolone acetate | Methylprednisolone acetate | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intralesional, Intramuscular, Intrasynovial, Soft Tissue | Nov. 10, 2023 | In Use | |
70121-1609-05 | 70121-1609 | Methylprednisolone acetate | Methylprednisolone acetate | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intralesional, Intramuscular, Intrasynovial, Soft Tissue | Nov. 10, 2023 | In Use | |
70518-2555-00 | 70518-2555 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 24, 2020 | Feb. 7, 2020 | In Use |
70518-2555-01 | 70518-2555 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | June 8, 2022 | In Use | |
70518-2555-02 | 70518-2555 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 21, 2023 | In Use | |
70518-3401-00 | 70518-3401 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 5, 2022 | In Use | |
70518-3401-01 | 70518-3401 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 5, 2022 | In Use | |
70518-3401-02 | 70518-3401 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 9, 2022 | In Use | |
70518-3401-03 | 70518-3401 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 11, 2023 | In Use | |
70518-3401-04 | 70518-3401 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | July 29, 2023 | In Use | |
70518-3401-05 | 70518-3401 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 15, 2023 | In Use | |
70518-3401-06 | 70518-3401 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 15, 2023 | In Use | |
70518-3401-07 | 70518-3401 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 6, 2023 | In Use | |
70518-3401-09 | 70518-3401 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 10, 2023 | In Use | |
70518-3910-00 | 70518-3910 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Nov. 7, 2023 | In Use | ||
70518-3910-02 | 70518-3910 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Nov. 10, 2023 | In Use | ||
71335-2273-01 | 71335-2273 | PREDNISONE | PREDNISONE | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 30, 2023 | In Use | |
71335-2273-02 | 71335-2273 | PREDNISONE | PREDNISONE | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 30, 2023 | In Use | |
60505-4779-05 | 60505-4779 | Pazopanib | Pazopanib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms | Oral | Oct. 19, 2023 | In Use | |
60505-4779-07 | 60505-4779 | Pazopanib | Pazopanib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms | Oral | Oct. 19, 2023 | In Use | |
70114-0340-01 | 70114-0340 | Toripalimab | LOQTORZI | 240.0 mg/6mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Oct. 27, 2023 | In Use | |
00006-5331-01 | 00006-5331 | Belzutifan | WELIREG | 40.0 mg/1 | Chemotherapy | Miscellaneous Agent | HIF-2 alpha | Oral | Aug. 13, 2021 | In Use | |
00006-5331-58 | 00006-5331 | Belzutifan | WELIREG | 40.0 mg/1 | Chemotherapy | Miscellaneous Agent | HIF-2 alpha | Oral | June 21, 2023 | In Use | |
00006-5331-59 | 00006-5331 | Belzutifan | WELIREG | 40.0 mg/1 | Chemotherapy | Miscellaneous Agent | HIF-2 alpha | Oral | June 21, 2023 | In Use | |
42023-0238-01 | 42023-0238 | METHYLPREDNISOLONE ACETATE | METHYLPREDNISOLONE ACETATE | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intralesional, INTRAMENINGEAL, Soft Tissue, Intramuscular | Nov. 2, 2023 | In Use | |
60505-6251-01 | 60505-6251 | Dexamethasone | Dexamethasone | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 1, 2023 | In Use | |
60505-6253-01 | 60505-6253 | Dexamethasone | Dexamethasone | 2.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 1, 2023 | In Use | |
60505-6254-01 | 60505-6254 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 1, 2023 | In Use | |
60687-0773-01 | 60687-0773 | Dexamethasone | Dexamethasone | 2.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 1, 2023 | In Use | |
67296-1886-03 | 67296-1886 | PREDNISONE | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 24, 2022 | In Use | |
67296-1886-05 | 67296-1886 | PREDNISONE | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 24, 2022 | In Use | |
25021-0219-20 | 25021-0219 | Decitabine | Decitabine | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Nov. 1, 2023 | In Use | |
21922-0041-12 | 21922-0041 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Nov. 6, 2023 | In Use | |
46708-0779-31 | 46708-0779 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct. 18, 2023 | In Use | |
62332-0779-31 | 62332-0779 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct. 18, 2023 | In Use | |
62135-0783-60 | 62135-0783 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct. 16, 2023 | In Use | |
62135-0784-12 | 62135-0784 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct. 16, 2023 | In Use | |
72189-0523-08 | 72189-0523 | Dexamethasone | Dexamethasone | 2.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 13, 2023 | In Use | |
46708-0659-02 | 46708-0659 | Carmustine | Carmustine | Chemotherapy | Alkylating Agent | Nitrosourea | Intravenous | Oct. 20, 2023 | In Use | ||
62332-0659-02 | 62332-0659 | Carmustine | Carmustine | Chemotherapy | Alkylating Agent | Nitrosourea | Intravenous | Oct. 20, 2023 | In Use | ||
72205-0198-01 | 72205-0198 | Carmustine | Carmustine | Chemotherapy | Alkylating Agent | Nitrosourea | Intravenous | Nov. 23, 2023 | In Use | ||
72603-0212-01 | 72603-0212 | Dexamethasone | Dexamethasone | 0.5 mg/.5mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 13, 2023 | In Use | |
72603-0213-01 | 72603-0213 | Dexamethasone | Dexamethasone | 0.75 mg/.75mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 13, 2023 | In Use | |
65219-0131-20 | 65219-0131 | Cyclophosphamide | Cyclophosphamide | 1.0 g/50mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Nov. 17, 2023 | In Use | |
65219-0133-20 | 65219-0133 | Cyclophosphamide | Cyclophosphamide | 2.0 g/100mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Nov. 17, 2023 | In Use | |
65219-0135-20 | 65219-0135 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/25mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Nov. 17, 2023 | In Use | |
81298-8110-01 | 81298-8110 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/25mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Jan. 1, 2022 | In Use | |
81298-8112-01 | 81298-8112 | Cyclophosphamide | Cyclophosphamide | 1.0 g/50mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Jan. 1, 2022 | In Use | |
81298-8114-01 | 81298-8114 | Cyclophosphamide | Cyclophosphamide | 2.0 g/100mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Jan. 1, 2022 | In Use | |
82111-0955-01 | 82111-0955 | Dexamethasone | Hemady | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 1, 2023 | In Use | |
82111-0955-02 | 82111-0955 | Dexamethasone | Hemady | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 1, 2023 | In Use | |
82511-0001-15 | 82511-0001 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Sept. 1, 2022 | In Use | |
82511-0002-50 | 82511-0002 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Feb. 16, 2022 | In Use | |
80725-0712-04 | 80725-0712 | Dutasteride | AVODART | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 15, 2022 | In Use | |
80725-0712-15 | 80725-0712 | Dutasteride | AVODART | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 15, 2022 | In Use | |
70518-3922-00 | 70518-3922 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Nov. 22, 2023 | In Use | ||
72603-0198-01 | 72603-0198 | Zoledronic acid | Zoledronic acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Nov. 1, 2023 | In Use | ||
68083-0615-01 | 68083-0615 | Zoledronic acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Nov. 8, 2023 | In Use | ||
70518-2486-00 | 70518-2486 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 15, 2019 | March 9, 2020 | In Use |
70518-2486-01 | 70518-2486 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 12, 2023 | In Use | |
68462-0896-10 | 68462-0896 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug. 9, 2023 | In Use | ||
68462-0897-10 | 68462-0897 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug. 9, 2023 | In Use | ||
55150-0450-01 | 55150-0450 | MITOMYCIN | MITOMYCIN | 5.0 mg/10mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Oct. 30, 2023 | In Use | |
55150-0451-01 | 55150-0451 | MITOMYCIN | MITOMYCIN | 20.0 mg/40mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Oct. 30, 2023 | In Use | |
55150-0452-01 | 55150-0452 | MITOMYCIN | MITOMYCIN | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Oct. 30, 2023 | In Use | |
43598-0308-23 | 43598-0308 | Plerixafor | Plerixafor | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Nov. 6, 2023 | In Use | |
00781-3532-12 | 00781-3532 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Nov. 1, 2023 | In Use | ||
00093-7769-24 | 00093-7769 | Everolimus | Everolimus | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct. 23, 2023 | In Use | |
42043-0390-00 | 42043-0390 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 12, 2016 | In Use | |
42043-0390-02 | 42043-0390 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 12, 2016 | In Use | |
42043-0390-20 | 42043-0390 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 12, 2016 | In Use | |
42043-0390-21 | 42043-0390 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 12, 2016 | In Use | |
42043-0390-40 | 42043-0390 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 12, 2016 | In Use | |
42747-0726-01 | 42747-0726 | Granisetron | Sancuso | 3.1 mg/24h | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Transdermal | Sept. 12, 2008 | In Use | |
42747-0726-72 | 42747-0726 | Granisetron | Sancuso | 3.1 mg/24h | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Transdermal | Sept. 12, 2008 | In Use | |
68727-0745-01 | 68727-0745 | (daunorubicin and cytarabine) liposome | Vyxeos | 100.0 mg/20mL, 44.0 mg/20mL | Chemotherapy | Antitumor Antibiotic & Antimetabolite | Anthracycline & Pyrimidine Analog | Intravenous | Aug. 3, 2017 | In Use | |
68727-0745-02 | 68727-0745 | (daunorubicin and cytarabine) liposome | Vyxeos | 100.0 mg/20mL, 44.0 mg/20mL | Chemotherapy | Antitumor Antibiotic & Antimetabolite | Anthracycline & Pyrimidine Analog | Intravenous | Aug. 3, 2017 | In Use | |
68727-0745-05 | 68727-0745 | (daunorubicin and cytarabine) liposome | Vyxeos | 100.0 mg/20mL, 44.0 mg/20mL | Chemotherapy | Antitumor Antibiotic & Antimetabolite | Anthracycline & Pyrimidine Analog | Intravenous | Aug. 3, 2017 | In Use | |
70518-2023-00 | 70518-2023 | Methylprednisolone sodium succinate | SOLU-MEDROL | 125.0 mg/2mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | April 15, 2019 | July 10, 2020 | In Use |
70518-2023-01 | 70518-2023 | Methylprednisolone sodium succinate | SOLU-MEDROL | 125.0 mg/2mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | April 15, 2019 | July 10, 2020 | In Use |
70518-2023-02 | 70518-2023 | Methylprednisolone sodium succinate | SOLU-MEDROL | 125.0 mg/2mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Aug. 27, 2021 | Aug. 30, 2021 | In Use |
70529-0045-01 | 70529-0045 | Dexamethasone Sodium Phosphate | Viadox | 10.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Aug. 1, 2018 | In Use | |
70529-0045-02 | 70529-0045 | Dexamethasone Sodium Phosphate | Viadox | 10.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Aug. 1, 2018 | In Use | |
70529-0045-05 | 70529-0045 | Dexamethasone Sodium Phosphate | Viadox | 10.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Aug. 1, 2018 | In Use | |
70529-0048-01 | 70529-0048 | Triamcinolone Acetonide | Protherix | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-Articular, Intramuscular | Sept. 1, 2018 | In Use | |
70529-0048-02 | 70529-0048 | Triamcinolone Acetonide | Protherix | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-Articular, Intramuscular | Sept. 1, 2018 | In Use | |
70529-0048-03 | 70529-0048 | Triamcinolone Acetonide | Protherix | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-Articular, Intramuscular | Sept. 1, 2018 | In Use | |
73358-0210-08 | 73358-0210 | Docetaxel Anhydrous | Docetaxel Anhydrous | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct. 17, 2022 | In Use | |
73358-0210-16 | 73358-0210 | Docetaxel Anhydrous | Docetaxel Anhydrous | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct. 17, 2022 | In Use | |
70518-2676-00 | 70518-2676 | Prednisone | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 7, 2020 | In Use | |
70518-2676-01 | 70518-2676 | Prednisone | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 22, 2020 | In Use | |
00378-7732-05 | 00378-7732 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | June 25, 2007 | Oct. 9, 2014 | In Use |
Found 10,000 results in 8 milliseconds — Export these results